We are live on ! Find out more
CMMB icon

Chemomab Therapeutics
CMMB

10 hedge funds and large institutions have $82.6M invested in Chemomab Therapeutics in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

74,081% more capital inflows, than outflows

Capital inflows: $143M | Capital outflows: $193K

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

100% more funds holding

Funds holding: 5 → 10 (+5)

25.24% more ownership

Funds ownership: 0% → 25.24% (+25%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
10
Holders Change
+5
Holders Change %
+100%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OrbiMed
OrbiMed
New York
+$128M
2
Maven Securities
Maven Securities
Jersey
+$6.3M
3
CVI Holdings
CVI Holdings
Delaware
+$4.66M
4
Boothbay Fund Management
Boothbay Fund Management
New York
+$3.07M
5
Meitav Investment House
Meitav Investment House
Israel
+$413K

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$120K
2
RegentAtlantic Capital
RegentAtlantic Capital
New Jersey
-$43K
3
Citadel Advisors
Citadel Advisors
Florida
-$21K
4
Morgan Stanley
Morgan Stanley
New York
-$8.56K

CMMB Hedge Fund Activity: Q1 2021 in Review

10 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2021, worth a combined $82.6M — up 23,773% from $346K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CMMB positions and 3 closed out — a net gain of 5 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $128M. The largest seller was Virtu Financial, exiting entirely with an estimated $120K sold.

  • 10 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2021, up from 5 in Q4 2020.
  • Funds reported $82.6M of Chemomab Therapeutics stock for Q1 2021, up 23,773% quarter-over-quarter.
  • 8 funds opened new Chemomab Therapeutics positions in Q1 2021 and 3 closed out, a net change of +5 holders.
  • The largest Chemomab Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $128M added.
  • The largest Chemomab Therapeutics seller in Q1 2021 was Virtu Financial, an estimated $120K sold.

Based on aggregated 13F filings for Q1 2021.